Progressive pulmonary fibrosis (PPF) is an increasingly recognised condition, defined in 2022 to address the progression of ...
Healthcare decision-makers are facing significant challenges that will intensify in the coming years as they work to address ...
AllianceQUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery 24.10.2024 / 09:30 CET/CESTThe issuer is solely responsible for the content of this ...
Dr Arshad Khanani previews the 2024 American Academy of Ophthalmology Annual Meeting, particularly the retina subspecialty day focusing on wet age-related macular degeneration (AMD), with highlights ...
One of the primary factors fueling the growth of the DOACs market is the rapid uptake and expected utilization within the ...
Global Pleural Diseases Therapeutics Market to Reach USD 9.4 Billion by 2033, Growing at a 6.5% CAGR
Global Pleural Diseases Therapeutics MarketThe global market for pleural diseases therapeutics is projected to experience ...
FRANKFURT: The CEO of pharmaceuticals giant Roche, opens new tab said authorities should block the takeover of contract drug ...
Madrigal faces financial challenges and competition for Rezdiffra. Read more to understand why MDGL stock is downgraded from ...
The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by ...
Boehringer's zongertinib and Bayer's BAY 2927088 ... Another oral HER2 agent – Spectrum Pharma's poziotinib – was rejected by the FDA as a second-line treatment for NSCLC with HER2 exon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback